Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1436 participants.
Also called NCT03176186
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,436 participants
- Sponsor
- Invero Pharma, Inc.
- Registry
-
NCT03176186
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Denmark
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT03176186. Randomized; single masking; primary purpose treatment. Start 2026-03 (anticipated); primary completion 2029-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
- Acronym
- XePOHCAS
- Condition
- Post-Cardiac Arrest Syndrome
- Intervention (Combination product)
- Xenon
- Lead sponsor
- Invero Pharma, Inc.
Record details
- Record id
cardio:ct-nct03176186- Content hash
7b5c0ec2fc7ac3686f52fc553787b89fa9ae8275f4e5e25489da324b371b6eb4